N'Senga Kinzonzi

N'Senga Kinzonzi

Neuroscience, Binghamton University, Binghamton, New York, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2023 in Cells
Verified
Journal Article
Open access
PDF file
CBCarla N Budrow
Carla N Budrow
KEKayla Elder
Kayla Elder
MCMichael Coyle
Michael Coyle
ACAshley Centner
Ashley Centner
NLNatalie Lipari
Natalie Lipari
CBChristopher Bishop
Christopher Bishop
Parkinson’s Disease (PD) is a neurodegenerative disorder characterized by motor symptoms that result from loss of nigrostriatal dopamine (DA) cells. While L-DOPA provides symptom alleviation, its chronic use often results in the development of L-DOPA-induced dyskinesia (LID). Evidence suggests that neuroplasticity within the serotonin (5-HT) system contributes to LID onset, persistence, and severity. This has been supported by research showing 5-HT compounds targeting 5-HT1A/1B receptors and/or the 5-HT transporter (SERT) can reduce LID. Recently, vortioxetine, a multimodal 5-HT compound developed for depression, demonstrated acute anti-dyskinetic effects. However, the durability and underlying pharmacology of vortioxetine’s anti-dyskinetic actions have yet to be delineated. To address these gaps, we used hemiparkinsonian rats in Experiment 1, examining the effects of sub-chronic vortioxetine on established LID and motor performance. In Experiment 2, we applied the 5-HT1A antagonist WAY-100635 or 5-HT1B antagonist SB-224289 in conjunction with L-DOPA and vortioxetine to determine the contributions of each receptor to vortioxetine’s effects. The results revealed that vortioxetine consistently and dose-dependently attenuated LID while independently, 5-HT1A and 5-HT1B receptors each partially reversed vortioxetine’s effects. Such findings further support the promise of pharmacological strategies, such as vortioxetine, and indicate that broad 5-HT actions may provide durable responses without significant side effects.

8 October 2025 in Experimental Neurology
Verified
Journal Article
Closed access
SVShruti Venkatesh
Shruti Venkatesh
NKN'Senga Kinzonzi
N'Senga Kinzonzi
AGAshley Galfano
Ashley Galfano
ASAizza Shah
Aizza Shah
JFJustin Franks
Justin Franks
CBChristopher Bishop
Christopher Bishop